{"id":"NCT02684279","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Dasotraline Binge Eating Disorder Extension Study","officialTitle":"An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-29","primaryCompletion":"2019-06-24","completion":"2019-06-24","firstPosted":"2016-02-17","resultsPosted":"2020-08-12","lastUpdate":"2020-08-12"},"enrollment":533,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Binge Eating Disorder"],"interventions":[{"type":"DRUG","name":"Dasotraline","otherNames":[]}],"arms":[{"label":"Dasotraline","type":"EXPERIMENTAL"}],"summary":"Binge Eating Disorder Extension Study.","primaryOutcome":{"measure":"Frequency and Severity of Suicidal Ideation Using the Columbia-suicide Severity Rating Scale (C-SSRS)","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Dasotraline","deltaMin":515,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":57,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":528},"commonTop":["Insomnia","Weight decreased","Dry mouth","Anxiety","Headache"]}}